Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Identification of the Wnt Signalling Protein, TCF7L2 As a Significantly Overexpressed Transcription Factor in AML

Siti Sarah Daud, MMedSc, Sara L Pumford, MPhil, Marie N Gilmour, PhD, Amanda F Gilkes, MSc, Alan K Burnett, MD, Robert Hills, MA, MSc, DPhil, Alex Tonks, PhD, Richard L Darley, PhD

Blood (2012) 120 (21): 1281.

https://doi.org/10.1182/blood.V120.21.1281.1281

Published: 2012

Journal Articles

Analysis of the Interaction of Induction Regimens with P-Glycoprotein Expression In Patients with Acute Myeloid Leukaemia: Results From the MRC AML15 Trial

Monica Pallis, PhD, Paul White, PhD, Robert Hills, MA, MSc, DPhil, Martin Grundy, BSc, Nigel H. Russell, MD, Alan Burnett

Blood (2010) 116 (21): 2724.

https://doi.org/10.1182/blood.V116.21.2724.2724

Published: 2010

Journal Articles

Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype

Azim Mohamedali, Robert Hills, MA, MSc, DPhil, Erick E Nasser, Atiyeh Abdallah, Austin G Kulasekararaj, Amanda Gilkes, Nicholas Lea, Alan Burnett, Ghulam J. Mufti, DM, FRCP, FRCPath

Blood (2010) 116 (21): 2729.

https://doi.org/10.1182/blood.V116.21.2729.2729

Published: 2010

Journal Articles

PDK1 Overexpression In Acute Myeloid Leukemia; Clinical Significance and Potential as a Therapeutic Target

Joanna Zabkiewicz, PhD, Lorna Pearn, Robert Hills, MA, MSc, DPhil, Rhys, Gareth Morgan, BSc, Alan Burnett, MD, Alex Tonks, PhD, Richard L Darley, PhD

Blood (2010) 116 (21): 2162.

https://doi.org/10.1182/blood.V116.21.2162.2162

Published: 2010

Journal Articles

A Polymorphism In the 3'UTR Region of ABCB1 Is Associated with Increased Allele Activity with Corresponding Increases In P-Glycoprotein Expression and Function

Nada Bajuaifer, Martin Grundy, BSc, Robert Hills, MA, MSc, DPhil, Nigel H. Russell, MD, Monica Pallis, PhD, Claire Seedhouse

Blood (2010) 116 (21): 3990.

https://doi.org/10.1182/blood.V116.21.3990.3990

Published: 2010

Journal Articles

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

Andrew H Wei, MBBS, PhD, Sonali Sadawarte, John Catalano, MBBS, FRACP, FRCPA, Robert Hills, MA, MSc, DPhil, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, Alan Burnett, Andrew Spencer, MD

Blood (2010) 116 (21): 3299.

https://doi.org/10.1182/blood.V116.21.3299.3299

Published: 2010

Journal Articles

A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls

Kate Stringaris, MD, MRCP, FRCPath, A. John Barrett, MD, Robert Hills, MA, MSc, DPhil, David C Linch, MD, FMedSci, Rosemary Gale, PhD, Christopher Allen, Paula Garland, MBBS, MRCP, Ruhena Sargent, Hugues de Lavallade, Abdullah Alsuliman, Ahmad Khoder, Dr, Ian H Gabriel, Dr, Takuya Sekine, Alan Burnett, Katayoun Rezvani, Jane F. Apperley

Blood (2010) 116 (21): 1697.

https://doi.org/10.1182/blood.V116.21.1697.1697

Published: 2010

Journal Articles

Distinct Regulation of β- and γ-Catenin throughout Hematopoietic Development Contrasts with Their Cooperative Roles In Acute Myeloid Leukemia.

Rhys Gareth Morgan, BSc, Lorna Pearn, Kate Liddiard, PhD, Robert Hills, MA, MSc, DPhil, Alan Burnett, MD, Alex Tonks, PhD, Richard L Darley, PhD

Blood (2010) 116 (21): 1573.

https://doi.org/10.1182/blood.V116.21.1573.1573

Published: 2010

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

Alan Burnett, Robert Hills, MA, MSc, DPhil, Ann Elizabeth Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, FRCP, FRCPath, William J. Kell, MD, MB, Keith Wheatley, John Yin, MD, Mary Frances McMullin, MD, Helen Dignum, David Bowen, Nigel H. Russell, MD

Blood (2010) 116 (21): 18.

https://doi.org/10.1182/blood.V116.21.18.18

Published: 2010

Journal Articles

Over-Expression of CD200 In Acute Myeloid Leukemia Mediates the Expansion of Regulatory T-Lymphocytes and Directly Inhibits Natural Killer Cell Tumor Immunity

Steven J Coles, PhD, Stephen Man, PhD, Robert Hills, MA, MSc, DPhil, Eddie CY Wang, PhD, Alan Burnett, MD, Richard L Darley, PhD, Alex Tonks, PhD

Blood (2010) 116 (21): 491.

https://doi.org/10.1182/blood.V116.21.491.491

Published: 2010

Journal Articles

Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations

Claire L Green, Catherine M Evans, Robert Hills, MA, MSc, DPhil, Lu Zhao, Alan Burnett, David C Linch, MD, Rosemary Gale, PhD

Blood (2010) 116 (21): 100.

https://doi.org/10.1182/blood.V116.21.100.100

Published: 2010

Journal Articles

Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively

Sylvie Freeman, Robert Hills, MA, MSc, DPhil, Paul Virgo, Steve Couzens, Mark W Lowdell, BSc, MSc, PhD, FRCPath, Christopher J McNamara, Paul White, Alan Burnett

Blood (2010) 116 (21): 2714.

https://doi.org/10.1182/blood.V116.21.2714.2714

Published: 2010

Journal Articles

The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy

Carol Guy, Amanda Gilkes, Rosemary Gale, PhD, David C. Linch, FRCP, Robert Hills, MA, MSc, DPhil, Alan K. Burnett, MD, FRCP

Blood (2008) 112 (11): 2978.

https://doi.org/10.1182/blood.V112.11.2978.2978

Published: 2008

Journal Articles

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Robert Hills, MA, MSc, DPhil, Susan O’Brien, M.D., Verena Karsten, PhD, Alan K. Burnett, MD, FRCP, Francis Giles, MD

Blood (2008) 112 (11): 2960.

https://doi.org/10.1182/blood.V112.11.2960.2960

Published: 2008

Journal Articles

Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison

Alan K. Burnett, MD, FRCP, Robert Hills, MA, MSc, DPhil, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, DPhil, Andres E. Virchis, FRCP, FRCPath, Nigel H. Russell, MD

Blood (2008) 112 (11): 2962.

https://doi.org/10.1182/blood.V112.11.2962.2962

Published: 2008

Journal Articles

CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.

Marc R Mansour, MBChB, MRCP, Rosemary Gale, PhD, Asim Khwaja, Martin Pule, Robert Hills, MA, MSc, DPhil, Alan K. Burnett, MD, FRCP, David Linch

Blood (2008) 112 (11): 3364.

https://doi.org/10.1182/blood.V112.11.3364.3364

Published: 2008

Journal Articles

Predictive Value of Minimal Residual Disease (MRD) Monitoring by RQ-PCR in WT1 Positive Patients Entered in the UK MRC AML-15 Trial

John Liu-Yin, FRCP, FRCPath, Michelle Sale, MSc, Sarah Daly, PhD, Robert Hills, MA, MSc, DPhil, Keith Wheatley, DPhil, Alan K. Burnett, MD, FRCP

Blood (2008) 112 (11): 697.

https://doi.org/10.1182/blood.V112.11.697.697

Published: 2008

Journal Articles

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

Rosemary Gale, PhD, Robert Hills, MA, MSc, DPhil, Claire Green, Yashma Patel, Amanda Gilkes, Michelle Lazenby, Keith Wheatley, DPhil, David C. Linch, FRCP, Alan Burnett

Blood (2008) 112 (11): 554.

https://doi.org/10.1182/blood.V112.11.554.554

Published: 2008

NARROW

Identification of the Wnt Signalling Protein, TCF7L2 As a Significantly Overexpressed Transcription Factor in AML

Analysis of the Interaction of Induction Regimens with P-Glycoprotein Expression In Patients with Acute Myeloid Leukaemia: Results From the MRC AML15 Trial

Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype

PDK1 Overexpression In Acute Myeloid Leukemia; Clinical Significance and Potential as a Therapeutic Target

A Polymorphism In the 3'UTR Region of ABCB1 Is Associated with Increased Allele Activity with Corresponding Increases In P-Glycoprotein Expression and Function

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls

Distinct Regulation of β- and γ-Catenin throughout Hematopoietic Development Contrasts with Their Cooperative Roles In Acute Myeloid Leukemia.

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

Over-Expression of CD200 In Acute Myeloid Leukemia Mediates the Expansion of Regulatory T-Lymphocytes and Directly Inhibits Natural Killer Cell Tumor Immunity

Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations

Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively

The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison

CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.

Predictive Value of Minimal Residual Disease (MRD) Monitoring by RQ-PCR in WT1 Positive Patients Entered in the UK MRC AML-15 Trial

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only